VIA
UTHR icon

Virtus Investment Advisers’s United Therapeutics UTHR Stock Holding History

Virtus Investment Advisers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
2,130
+423
+25% +$238K 0.27% 185
2026
Q1 		$1.01M Buy
1,707
+325
+24% +$162K 0.28% 140
2025
Q4 		$673K Sell
1,382
-171
-11% -$79.6K 0.18% 189
2025
Q3 		$651K Hold
1,553
– – 0.19% 181
2025
Q2 		$446K Buy
1,553
+559
+56% +$167K 0.15% 200
2025
Q1 		$306K Buy
+994
New +$341K 0.08% 240

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Virtus Investment Advisers's UTHR Position: Q2 2026 in Review

Virtus Investment Advisers increased its United Therapeutics (UTHR) stake by 25% in Q2 2026, buying an estimated $238K and bringing the position to 2,130 shares worth $1.15M. The position accounts for 0.27% of the portfolio, ranked #185.

Virtus Investment Advisers first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Virtus Investment Advisers held 2,130 shares of United Therapeutics worth $1.15M as of Q2 2026.
  • Virtus Investment Advisers bought 423 United Therapeutics shares in Q2 2026, an estimated $238K.
  • United Therapeutics made up 0.27% of Virtus Investment Advisers's portfolio in Q2 2026, its #185 holding.
  • Virtus Investment Advisers first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.